Kosuke Sakurai

Dr. Kosuke Sakurai

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HNHaruka Nakamura
Haruka Nakamura
HKHiroyuki Kojima
Hiroyuki Kojima
KMKohei Maeda
Kohei Maeda
KSKosuke Sakurai
Kosuke Sakurai
TTToshihiro Tanioka
Toshihiro Tanioka
TITakeo Isozaki
Takeo Isozaki
Rheumatoid arthritis (RA), a chronic autoimmune condition, causes irreversible bone destruction. A disintegrin and metalloprotease 10 (ADAM-10) has been implicated in inflammatory processes in RA. We investigated the potential role of ADAM-10 in osteoblast mineralization and RA-associated bone destruction. Serum ADAM-10 levels in RA patients were measured by ELISA, and ADAM-10 expression in osteoblasts was assessed by Western blotting. Collagen-induced arthritis (CIA) mice were treated intraperitoneally with the ADAM-10 inhibitor GI254023X (100 mg/kg) for three weeks. Arthritis and bone destruction were evaluated by macroscopic, immunohistochemical, histological, and micro-CT analyses. The effects of ADAM-10 inhibition on primary osteoblast mineralization were also assessed by Alizarin Red S staining. Serum ADAM-10 levels in patients with RA tended to be higher at Stage III of the Steinbrocker classification. In CIA mice, ADAM-10 inhibition attenuated weight loss, paw swelling, and arthritis scores and suppressed bone destruction. ADAM-10 inhibition also significantly reduced Rankl expression in knee joints. Furthermore, the inhibition reversed the suppression of primary osteoblast mineralization induced by TNF-α. Pharmacological inhibition of ADAM-10 attenuated experimental arthritis and bone destruction and improved osteoblast mineralization, suggesting that ADAM-10 may contribute to inflammatory bone destruction in RA.